Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-04-29 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
关于召开2023年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2023 Annual General Meeting (AGM) of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes details about the meeting date, voting methods, agenda items to be discussed and voted on, and instructions for shareholders. The document does not contain the actual annual report, financial statements, or voting results, but rather the announcement and logistical information for the upcoming AGM. The document length is 3610 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2024-04-29 Chinese
2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2023 Annual Report Summary" of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It contains detailed financial data for the year 2023, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, industry analysis, and risk disclosures. The document is comprehensive and covers the company's operating results, financial condition, and future plans, which are typical contents of an Annual Report. The length of the document (over 14,000 characters) and the presence of detailed financial and operational data confirm it is the report itself, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2024-04-29 Chinese
上会会计师事务所（特殊普通合伙）关于上海宣泰医药科技股份有限公司2023年度募集资金存放与使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Assurance Report) regarding the "募集资金存放与使用情况" (the deposit and use of raised funds) for the year 2023 by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It is issued by a certified public accounting firm and includes detailed information about the management, storage, and actual use of the company's raised funds during 2023. The document references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange related to the management and use of raised funds. It contains detailed financial data on fundraising amounts, usage, balances, investment products, and changes in fundraising projects. This type of report is a standalone audit or assurance report focused on the company's fundraising capital management and usage, not a full annual or interim financial report. It is not a simple announcement or certification letter but a substantive assurance report on fundraising capital usage. Therefore, the document fits the category of an Audit Report / Information (AR).
2024-04-29 Chinese
2023年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) issued by a certified public accounting firm for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It contains detailed audit opinions, basis for the audit, key audit matters, management responsibilities, and auditor responsibilities. It includes financial statements such as balance sheets and income statements for the year ended December 31, 2023, and discusses audit procedures and findings. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report rather than a full annual report or other filing types. Therefore, the appropriate classification is Audit Report / Information (AR).
2024-04-29 Chinese
2023年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising (募集资金) activities for the year 2023, including the amount raised, usage, management, changes in investment projects, and compliance with regulatory requirements. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes auditor and sponsor opinions on the use of the funds. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2023. It contains substantive financial data and detailed explanations about the fundraising and usage, including tables of amounts, project changes, and investment progress. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a full annual or interim report, nor a regulatory filing or certification. Therefore, the appropriate classification is CAP.
2024-04-29 Chinese
第二届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes approvals of various reports such as the 2023 Annual Report, 2023 Annual Audit Report, 2024 Q1 Report, and other governance and financial matters. The document repeatedly states that the detailed reports are disclosed separately on the Shanghai Stock Exchange website and that these resolutions will be submitted to the 2023 Annual General Meeting for approval. The document itself is a board meeting resolution announcement, not the actual reports or financial statements. It contains no substantive financial data or full report content but rather summaries and approvals of reports and proposals. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management changes or approvals. The document length is 4224 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2024-04-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.